activeDCM - Interventional Clinical Trial of Individualized Activity and Exercise Programs to Improve Outcome in Dilated Cardiomyopathy Guided by Longitudinal Biosensing With Apple Watch
Launched by UNIVERSITY HOSPITAL HEIDELBERG · Apr 21, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The activeDCM trial is exploring how personalized exercise programs can help patients with dilated cardiomyopathy, a condition that affects the heart's ability to pump blood effectively. In this study, 300 patients will be monitored over 13 months using an Apple Watch to track their activity levels and symptoms. Researchers want to see if these tailored exercise plans can improve patients' maximum oxygen intake—a measure of how well their heart and lungs work together—along with their overall well-being and heart function. They will also check the safety of these exercise programs and look for changes in certain molecules in the blood that might indicate how the training impacts heart health.
To participate in this study, individuals need to be between 18 and 65 years old, diagnosed with non-ischemic dilated cardiomyopathy, and have a specific heart function measurement (called ejection fraction) of 45% or lower. Unfortunately, those with certain physical disabilities or recent health issues, like fainting, may not be eligible. Participants will receive an Apple Watch, which will help them stay engaged with their exercise program while researchers gather important information about how personalized exercise can benefit heart health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of non-ischemic, dilated cardiomyopathy (DCM)
- • EF ≤ 45%
- • NYHA I-III
- • Age 18 to 65 years
- • The patient understood the study concept and the declaration of consent and signed and dated the declaration of consent
- Exclusion Criteria:
- • Physical disability that is not compatible with exercise in the study
- • Orthopedic diseases such as osteoarthritis or changes in the spine that lead to restrictions that are not compatible with exercise in the study
- • Syncope within the past 3 months
- • Pregnancy
About University Hospital Heidelberg
University Hospital Heidelberg is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a key player in translational medicine, the hospital integrates cutting-edge scientific discoveries with patient care, facilitating a robust environment for clinical trials. With a diverse range of specialties and a multidisciplinary approach, University Hospital Heidelberg aims to improve therapeutic outcomes and enhance the quality of life for patients through evidence-based practices. The institution is dedicated to fostering collaborations with academic partners, industry stakeholders, and regulatory bodies to drive forward-looking research initiatives and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Heidelberg, Baden Württemberg, Germany
Heidelberg, , Germany
Patients applied
Trial Officials
Benjamin Meder, Prof. Dr.
Principal Investigator
University Hospital Heidelberg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials